TRAW

#4789
Traws Pharma, Inc. - Common Stock
0.5 6 USD
-0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.56
0.56
Jahresspanne
0.43
3.25
Tagesänderung
-1.75%
Monatliche Änderung
+14.29%
6 month change
-66.27%
Jahresänderung
-65.64%
Vorheriger Schlusskurs
0.5 7
Open
0.5 6
Tief
0.5 6
Hoch
0.5 6
Volumen
1
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Traws Pharma, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K

Traws Pharma, Inc. current report, Q3 FY2023

Full document

Business Context and Reporting Period

This Form 8-K filing by Onconova Therapeutics, Inc. (ONTX) reports on the results of its 2023 Annual Meeting of Stockholders held on August 10, 2023. The meeting was previously adjourned due to a lack of quorum but successfully convened with 10,515,016 shares represented. Note: The request metadata references "Traws Pharma, Inc.," but the filing text explicitly identifies the registrant as Onconova Therapeutics, Inc.

Key Financial Metrics

This filing is a current report regarding corporate governance and shareholder voting. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.

Material Changes and Voting Results

Stockholders voted on three proposals at the Annual Meeting:

  • Proposal 1 (Election of Directors): All eight nominees were elected. Votes ranged from approximately 5.54 million to 5.67 million "For" votes, with "Withheld" votes ranging from approximately 1.26 million to 1.39 million. There were 3,588,614 broker non-votes for each nominee.
  • Proposal 2 (Say-on-Pay): The advisory proposal to approve executive compensation was approved. Results: 4,959,016 For, 1,066,808 Against, 900,578 Abstain, and 3,588,614 Broker Non-Votes.
  • Proposal 3 (Auditor Ratification): The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified. Results: 9,271,526 For, 368,397 Against, 875,093 Abstain, and 0 Broker Non-Votes.

Guidance, Outlook, and Management Commentary

Regarding the "say-on-pay" vote (Proposal 2), the Compensation Committee stated it will consider the voting results and feedback from the ongoing stockholder engagement program when setting future executive compensation. No financial guidance, risk factors, or unusual items were disclosed in this specific filing.

Investor Verification Checklist

  • Verify the company name discrepancy between the request metadata ("Traws Pharma") and the filing text ("Onconova Therapeutics").
  • Review the significant number of broker non-votes (3,588,614) on director elections to understand potential proxy voting dynamics.
  • Confirm the ratification of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2023.
  • Check subsequent filings for the company's financial performance, as this 8-K contains no financial statements.